Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. GI Insights

Beyond Antibiotics: Treatment Advances for Recurrent CDIs

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Of the 365,200 patients that are diagnosed with Clostridioides difficile infections (CDIs) each year, at least 40 percent will face recurrent infections. Fortunately, major therapeutic advances in the past 5 years can help shut down that cycle of recurrence. Joining Dr. Charles Turck to talk about how microbiome-based agents can supplement the standard-of-care antimicrobials for recurrent CDIs is Dr. Paul Feuerstadt, Associate Clinical Professor of Medicine at Yale University School of Medicine.

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Of the 365,200 patients that are diagnosed with Clostridioides difficile infections (CDIs) each year, at least 40 percent will face recurrent infections. Fortunately, major therapeutic advances in the past 5 years can help shut down that cycle of recurrence. Joining Dr. Charles Turck to talk about how microbiome-based agents can supplement the standard-of-care antimicrobials for recurrent CDIs is Dr. Paul Feuerstadt, Associate Clinical Professor of Medicine at Yale University School of Medicine.

Schedule9 Dec 2024